Outcomes of patients with melioidosis treated with cotrimoxazole alone for eradication therapy

N/ACitations
Citations of this article
43Readers
Mendeley users who have this article in their library.

Abstract

We retrospectively reviewed a 10-year experience of administration of cotrimoxazole alone in 31 patients compared with 109 patients who received conventional eradication therapy (cotrimoxazole plus doxycycline). The baseline characteristics, the clinical manifestations, the initial intravenous antibiotic treatments, and the mean duration of eradication therapy between the two groups were similar. The culture-confirmed recurrences among the patients who received cotrimoxazole alone and those who received the conventional regimen were not significantly different (1/31 [3.2%] versus 5/109 [4.5% odds ratio = 0.69 [95% confidence interval [CI] = 0.08-6.17]). Gastrointestinal side effects were more common among the conventional regimen group (28/109 [25.7%] versus 2/31 [6.5%], P = 0.02) and the proportion of patients who could complete at least 20 weeks of therapy without having switched to the other regimen was significantly lower (91/109 [83.5%] versus 31/31 [100.0%] P = 0.01). Cotrimoxazole alone is as effective as and better tolerated than cotrimoxazole plus doxycycline for the eradication treatment of melioidosis. Copyright © 2012 by The American Society of Tropical Medicine and Hygiene.

Cite

CITATION STYLE

APA

Chusri, S., Hortiwakul, T., Charoenmak, B., & Silpapojakul, K. (2012). Outcomes of patients with melioidosis treated with cotrimoxazole alone for eradication therapy. American Journal of Tropical Medicine and Hygiene, 87(5), 927–932. https://doi.org/10.4269/ajtmh.2012.12-0136

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free